| Literature DB >> 29342911 |
Yingyu Zhou1,2, Cuilin Cheng3,4, Denis Baranenko5, Jiaping Wang6, Yongzhi Li7,8, Weihong Lu9,10.
Abstract
The active compounds in Acanthopanax senticosus (AS) have different pharmacokinetic characteristics in mouse models. Cmax and AUC of Acanthopanax senticosus polysaccharides (ASPS) were significantly reduced in radiation-injured mice, suggesting that the blood flow of mouse was blocked or slowed, due to the pathological state of ischemia and hypoxia, which are caused by radiation. In contrast, the ability of various metabolizing enzymes to inactivate, capacity of biofilm transport decrease, and lessening of renal blood flow accounts for radiation, resulting in the accumulation of syringin and eleutheroside E in the irradiated mouse. Therefore, there were higher pharmacokinetic parameters-AUC, MRT, and t1/2 of the two compounds in radiation-injured mouse, when compared with normal mouse. In order to investigate the intrinsic mechanism of AS on radiation injury, AS extract's protective effects on brain, the main part of mouse that suffered from radiation, were explored. The function of AS extract in repressing expression changes of radiation response proteins in prefrontal cortex (PFC) of mouse brain included tubulin protein family (α-, β-tubulin subunits), dihydropyrimidinase-related protein 2 (CRMP2), γ-actin, 14-3-3 protein family (14-3-3ζ, ε), heat shock protein 90β (HSP90β), and enolase 2. The results demonstrated the AS extract had positive effects on nerve cells' structure, adhesion, locomotion, fission, and phagocytosis, through regulating various action pathways, such as Hippo, phagosome, PI3K/Akt (phosphatidylinositol 3 kinase/protein kinase B), Neurotrophin, Rap1 (Ras-related protein RAP-1A), gap junction glycolysis/gluconeogenesis, and HIF-1 (Hypoxia-inducible factor 1) signaling pathways to maintain normal mouse neurological activity. All of the results indicated that AS may be a promising alternative medicine for the treatment of radiation injury in mouse brain. It would be tested that whether the bioactive ingredients of AS could be effective through the blood-brain barrier in the future.Entities:
Keywords: Acanthopanax senticosus (AS); brain injury; pharmacokinetic; proteomics
Mesh:
Substances:
Year: 2018 PMID: 29342911 PMCID: PMC5796108 DOI: 10.3390/ijms19010159
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Content of the active compounds in different tissues of Acanthopanax senticosus (AS).
| Compounds | Content of the Active Compounds (%) | ||||
|---|---|---|---|---|---|
| Tissue of Lesser Khingan Mountain | |||||
| Root | Stem | Leaf | Fruit | Average | |
| Polysaccharides | 6.05 ± 0.25 | 8.09 ± 0.37 | 4.12 ± 0.19 | 3.08 ± 0.13 | 5.33 ± 0.24 |
| Flavones | 14.25 ± 0.66 | 9.26 ± 0.45 | 4.02 ± 0.17 | 9.58 ± 0.50 | 9.28 ± 0.45 |
| Syringin | 1.44 ± 0.06 | 1.86 ± 0.08 | 0.09 ± 0.01 | 0.02 ± 0.001 | 3.40 ± 0.04 |
| Eleutheroside E | 3.17 ± 0.12 | 4.14 ± 0.25 | 0.18 ± 0.01 | 0.04 ± 0.002 | 1.88 ± 0.10 |
Figure 1Pharmacokinetics curve of Acanthopanax senticosus polysaccharide (ASPS) in mice’s serum.
Pharmacokinetics parameters of ASPS in mice’s serum.
| Parameters | ASPS | |
|---|---|---|
| Normal-AS-Treatment | Radiation-AS-Treatment | |
| 1.18 × 101 ± 6.85 × 10−1 | 6.14 × 100 ± 7.82 × 10−1 ** | |
| 2.50 × 10−1 ± 3.81 × 10−1 | 5.00 × 10−1 ± 1.44 × 10−1 | |
| 1.15 × 106 ± 8.13 × 104 | 1.01 × 106 ± 1.24 × 105 | |
| 1.43 × 107 ± 3.00 × 106 | 8.92 × 106 ± 8.81 × 105 * | |
| 1.59 × 101 ± 9.63 × 10−1 | 9.07 × 100 ± 1.95 × 10−1 ** | |
| 9.83 × 10−4 ± 1.76 × 10−4 | 8.19 × 10−4 ± 8.33 × 10−5 | |
| 5.76 × 10−5 ± 6.12 × 10−6 | 9.25 × 10−5 ± 8.50 × 10−6 * | |
* p < 0.05; ** p < 0.01 (compared with normal-AS-treatment group).
Figure 2Pharmacokinetics curves of Syringin and Eleutheroside E in mice’s serum. (A) Pharmacokinetics curve of Syringin in mice’s serum. (B) Pharmacokinetics curve of Eleutheroside E in mice’s serum.
Pharmacokinetics parameters of Syringin and Eleutheroside E in mice’s serum.
| Parameters | Syringin | Eleutheroside E | ||
|---|---|---|---|---|
| Normal-AS-Treatment | Radiation-AS-Treatment | Normal-AS-Treatment | Radiation-AS-Treatment | |
| 6.47 × 100 ± 6.61 × 10−1 | 9.72 × 100 ± 3.81 × 10−1 *** | 1.72 × 101 ± 7.22 × 10−1 | 2.51 × 101 ± 5.56 × 100 ** | |
| 5.00 × 10−1 ± 1.83 × 10−1 | 5.00 × 10−1 ± 2.37 × 10−1 | 5.00 × 10−1 ± 1.92 × 10−1 | 5.00 × 10−1 ± 3.21 × 10−1 | |
| 1.70 × 102 ± 7.41 × 100 | 2.12 × 102 ± 1.97 × 101 *** | 2.07 × 103 ± 6.61 × 102 | 2.11 × 103 ± 5.93 × 102 | |
| 2.83 × 102 ± 3.23 × 101 | 5.34 × 102 ± 6.54 × 10−1 | 9.93 × 103 ± 1.81 × 103 | 1.20 × 104 ± 3.63 × 103 * | |
| 4.58 × 100 ± 6.12 × 10−1 | 5.95 × 100 ± 7.30 × 10−1 | 1.48 × 101 ± 5.97 × 10−1 | 2.11 × 101 ± 7.01 × 10−1 ** | |
| 2.72 × 101 ± 8.73 × 10−1 | 2.17 × 101 ± 9.19 × 10−1 ** | 2.06 × 100 ± 8.87 × 10−1 | 2.49 × 100 ± 4.49 × 10−1 * | |
| 2.91 × 100 ± 5.65 × 10−1 | 1.54 × 100 ± 1.86 × 10−1 | 8.30 × 10−2 ± 7.32 × 10−3 | 6.89 × 10−2 ± 7.17 × 10−3 ** | |
* p < 0.05; ** p < 0.01; *** p < 0.001 (compared with normal-AS-treatment group).
Figure 3Two-dimensional (2D) gels showing the differences in protein expression and modifications among different groups. (A) Normal control group. (B) Model set. (C) AS extract treatment group. (1. SSP0314; 2. SSP3307; 3. SSP3311; 4. SSP4422; 5. SSP8116; 6. SSP2814; 7. SSP3315; and 8. SSP7119).
Basic information of differential proteins (partial).
| Sample | Protein Name | Accession No | Homology Model | Score | Identity | Gene Name |
|---|---|---|---|---|---|---|
| 3307↑ | Tubulin α-1A chain | gi|55977479 | 779 | 99.54 | ||
| 3315↓ | Tubulin β-2A chain | gi|81885934 | 1020 | 100 | ||
| 4422↑ | γ-actin | gi|809561 | 912 | 100 | ||
| 8116↓ | 14-3-3 protein ζ | gi|148676868 | 644 | 100 | ||
| 7119↓ | 14-3-3 protein ξ (Homosapiens) | gi|26344914 | 516 | 99.61 | ||
| 0314↑ | Heat shock protein HSP 90-β | gi|341941065 | 685 | 100 | ||
| 2814↓ | dihydropyrimidinase-related protein 2 | gi|568986628 | 1150 | 98.6 | ||
| 3311↓ | enolase 2, γ neuronal | gi|148667340 | 595 | 100 |
↑: The protein’s gray scale was significantly higher in AS treatment group than the model set; ↓: The protein’s gray scale was significantly lower in AS treatment group than model set.
Figure 4Summary information of each query protein.
Figure 5Enriched Gene Ontology.
Figure 6Significantly different Biological Processes.
Figure 7Significantly different Cell Componentes.
Figure 8Significantly different Molecular Functiones.
Figure 9Class of enriched KEGG Pathways.
Figure 10Significantly different KEGG pathways.
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of differential proteins (partial).
| Sample | Protein Name | KEGG Pathways |
|---|---|---|
| 3307 | α-tubulin | mmu04540, Gap junction|mmu04210, Apoptosis|mmu04145, Phagosome |
| 3155 | β-tubulin | mmu04540, Gap junction|mmu04145, Phagosome |
| 4422 | γ-actin | mmu04530, Tight junction|mmu04670, Leukocyte transendothelial migration|mmu05414, Dilated cardiomyopathy|mmu04015, Rap1 signaling pathway|mmu05416, Viral myocarditis|mmu05410, Hypertrophic cardiomyopathy (HCM)|mmu04510, Focal adhesion|mmu05205, Proteoglycans in cancer|mmu04520, Adherens junction|mmu04611, Platelet activation|mmu05100, Bacterial invasion of epithelial cells|mmu04210, Apoptosis|mmu04145, Phagosome|mmu05412, Arrhythmogenic right ventricular cardiomyopathy (ARVC)|mmu05132, Salmonella infection|mmu04390, Hippo signaling pathway|mmu04810, Regulation of actin cytoskeleton|mmu04921, Oxytocin signaling pathway|mmu04919, Thyroid hormone signaling pathway|mmu05164, Influenza A |
| 8116 | 14-3-3ζ | mmu05203, Viral carcinogenesis|mmu05161, Hepatitis B|mmu04114, Oocyte meiosis|mmu05169, Epstein-Barr virus infection|mmu04110, Cell cycle|mmu04151, PI3K-Akt signaling pathway|mmu04390, Hippo signaling pathway |
| 7119 | 14-3-3ε | mmu05203, Viral carcinogenesis|mmu04722, Neurotrophin signaling pathway|mmu04114, Oocyte meiosis|mmu05169, Epstein-Barr virus infection|mmu04110, Cell cycle|mmu04151, PI3K-Akt signaling pathway|mmu04390, Hippo signaling pathway |
| 0314 | HSP 90-β | mmu04915, Estrogen signaling pathway|mmu04914, Progesterone-mediated oocyte maturation|mmu04621, NOD-like receptor signaling pathway|mmu04612, Antigen processing and presentation|mmu05215, Prostate cancer|mmu04141, Protein processing in endoplasmic reticulum|mmu04151, PI3K-Akt signaling pathway|mmu05200, Pathways in cancer |
| 2814 | CRMP2 | mmu04360, Axon guidance |
| 3311 | ENO2 | mmu01100, Metabolic pathways|mmu01200, Carbon metabolism|mmu04066, HIF-1 signaling pathway|mmu01230, Biosynthesis of amino acids|mmu00010, Glycolysis/Gluconeogenesis|mmu03018, RNA degradation |
Figure 11Interactions among differential proteins (A) Interaction diagram (B) Interaction network among differential proteins.